How does CNSP's PB Ratio compare to its peers?

CNSP is expensive based on its Price-To-Book Ratio (1.8x) compared to the peer average (1x).

How does CNSP's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

CNSP is expensive based on its Price-To-Book Ratio (1.8x) compared to the US Pharmaceuticals industry average (1.7x).

What is CNSP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate CNSP's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of CNSP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate CNSP's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

CNS Pharmaceuticals (Nasdaq:CNSP) - Stock Price, News & Analysis

CNSP Stock Overview

A clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. More details

CNSP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($6M)

Makes less than USD$1m in revenue ($0)

Volatile share price over the past 3 months compared to the US market

+ 1 more risk

CNS Pharmaceuticals, Inc. Competitors

Evoke Pharma

NasdaqCM:EVOK

US$6.4m

Adial Pharmaceuticals

NasdaqCM:ADIL

US$6.5m

Polydex Pharmaceuticals

OTCPK:POLX.F

US$6.8m

Mystic Holdings

OTCPK:MSTH

US$5.8m

Price History & Performance

Summary of all time highs, changes and price drops for CNS Pharmaceuticals
Historical stock prices
Current Share Price	US$0.12
52 Week High	US$119.00
52 Week Low	US$0.096
Beta	1.05
11 Month Change	-5.90%
3 Month Change	-30.89%
1 Year Change	-99.90%
33 Year Change	-99.99%
5 Year Change	-100.00%
Change since IPO	-100.00%

Recent updates

CNS Pharmaceuticals reports Q2 results

Aug 15

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

Dec 04

CNS Pharmaceuticals sinks after pricing equity offering of $10M

Dec 23

Shareholder Returns

	CNSP	US Pharmaceuticals	US Market
7D	18.4%	1.6%	2.2%
1Y	-99.9%	9.9%	31.6%

Return vs Industry: CNSP underperformed the US Pharmaceuticals industry which returned 10% over the past year.

Return vs Market: CNSP underperformed the US Market which returned 31.7% over the past year.

Price Volatility

Is CNSP's price volatile compared to industry and market?
CNSP volatility
CNSP Average Weekly Movement	13.6%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: CNSP's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CNSP's weekly volatility has decreased from 21% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2017	4	John Climaco	www.cnspharma.com

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNS Pharmaceuticals, Inc. Fundamentals Summary

How do CNS Pharmaceuticals's earnings and revenue compare to its market cap?
CNSP fundamental statistics
Market cap	US$6.17m
Earnings (TTM)	-US$17.06m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Is CNSP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CNSP income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$17.06m
Earnings	-US$17.06m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.34
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.9%

How did CNSP perform over the long term?

See historical performance and comparison

CNSP Stock Overview

Risk Analysis

CNS Pharmaceuticals, Inc. Competitors

NasdaqCM:EVOK

US$6.4m

NasdaqCM:ADIL

US$6.5m

OTCPK:POLX.F

US$6.8m

OTCPK:MSTH

US$5.8m

Price History & Performance

Recent News & Updates

CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million.

The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024

Recent updates

CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million.

The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. announced a financing transaction

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3725 million.

New major risk - Share price stability

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq

CNS Pharmaceuticals Provides Non-Compliance Update

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

New major risk - Negative shareholders equity

CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland

Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (Gbm)

CNS Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement Pursuant to Nasdaq’s Listing Rule 5550(b)(1)

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Investigator-Initiated Phase 1B/2 Trial to Be Conducted At the Pomeranian Medical University in Poland

Cns Pharmaceuticals, Inc. Appoints Faith Charles as Independent Member and as Chairperson of the Board of Directors

CNS Pharmaceuticals, Inc Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Insufficient new directors

CNS Pharmaceuticals, Inc. Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Provides A Clinical Update of Its Anti-Cancer Drug Candidates Currently in Development for the Treatment of Primary and Metastatic Brain and CNS Cancer

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2022

CNS Pharmaceuticals Inc. Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Price target increased to US$10.00

Insufficient new directors

CNS Pharmaceuticals, Inc. Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals, Inc. announced that it expects to receive $11.500001 million in funding

Insufficient new directors

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

CNS Pharmaceuticals, Inc. Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

FDA Grants Fast Track Designation to CNS Pharmaceuticals, Inc. for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals Berubicin Trial is on Schedule to Commence in March 2021

WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announces Berubicin Supply Agreement for the Upcoming Clinical Trials

WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

New 90-day high: US$3.50

CNS Pharmaceuticals Announces It Has Been Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application

CNS Pharmaceuticals sinks after pricing equity offering of $10M

CNS Pharmaceuticals, Inc. Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

New 90-day high: US$2.89

Shareholder Returns

Price Volatility

About the Company

CNS Pharmaceuticals, Inc. Fundamentals Summary

0.0x